Can antiviral therapy of chronic hepatitis B prevent the development of hepatocellular carcinoma?

Thursz, Mark; Brown, Ashley
August 2011
Gut;Aug2011, Vol. 60 Issue 8, p1025
Academic Journal
In this article, the authors discuss the effectiveness of antiviral therapy for chronic hepatitis B in preventing the development of hepatocellular carcinoma (HCC). The authors cite the differences between the 2004 study of Y. F. Liaw and colleagues and G. V. Papatheodoridis and colleagues which include the design of the study, the patients' age, and viral genotypes. The authors suggest a placebo-controlled trial in demonstrating nucleos(t)ide analogues' (NAs) effectiveness in reducing HCC risk.


Related Articles

  • Long-Term Treatment Efficacy and Safety of Clevudine Therapy in Naïve Patients with Chronic Hepatitis B. Bum Su Choung; In Hee Kim; Byung Jun Jeon; Seok Lee; Seong Hun Kim; Sang Wook Kim; Seung Ok Lee; Soo Teik Lee; Dae-Ghon Kim // Gut & Liver;Oct2012, Vol. 6 Issue 4, p486 

    Background/Aims: Clevudine (CLV) has potent antiviral activity against chronic hepatitis B (CHB) virus infection. The long-term efficacy and safety of CLV therapy in naïve patients with CHB were investigated. Methods: In this retrospective study, 152 naïve Korean patients with CHB who...

  • Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen—Negative Chronic Hepatitis B. Hadziyannis, Stephanos J.; Tassopoulos, Nicolaos C.; Heathcote, E. Jenny; Chang, Ting-Tsung; Kitis, George; Rizzetto, Mario; Marcellin, Patrick; Lim, Seng Gee; Goodman, Zachary; Wulfsohn, Michael S.; Xiong, Shelly; Fry, John; Brosgart, Carol L. // New England Journal of Medicine;2/27/2003, Vol. 348 Issue 9, p800 

    Background: Adefovir dipivoxil, a nucleotide analogue, demonstrated clinically significant antiviral activity in patients with chronic hepatitis B in phase 1 and 2 clinical trials. Methods: We randomly assigned 185 patients with chronic hepatitis B who were negative for hepatitis B e antigen...

  • Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen—Positive Chronic Hepatitis B. Marcellin, Patrick; Chang, Ting-Tsung; Lim, Seng Gee; Tong, Myron J.; Sievert, William; Shiffman, Mitchell L.; Jeffers, Lennox; Goodman, Zachary; Wulfsohn, Michael S.; Xiong, Shelly; Fry, John; Brosgart, Carol L. // New England Journal of Medicine;2/27/2003, Vol. 348 Issue 9, p808 

    Background: In preclinical and phase 2 studies, adefovir dipivoxil demonstrated potent activity against hepatitis B virus (HBV), including lamivudine-resistant strains. Methods: We randomly assigned 515 patients with chronic hepatitis B who were positive for hepatitis B e antigen (HBeAg) to...

  • Chronic hepatitis B virus infection: treatment strategies for the next millennium. Malik, Arshad H.; Lee, William M.; Malik, A H; Lee, W M // Annals of Internal Medicine;05/02/2000, Vol. 132 Issue 9, p723 

    Chronic hepatitis B virus (HBV) infection is a leading cause of cirrhosis and hepatocellular carcinoma worldwide. Its prevalence approaches 10% in hyperendemic areas, such as southeast Asia, China, and Africa. Although chronic HBV infection is seen less frequently in North America and Europe, an...

  • Prevalence of Hepatitis B virus genotypes with HBsAg positive patients in the Northern of Iran (Mazandaran) during 2010-2011. Mohammadreza, Haghshenas; Tahora, Mosavi; Alireza, Rafiee; Vahid, Hosseini; Zahra, Hosseinikha // HealthMed;2012, Vol. 6 Issue 5, p1568 

    Background: HBV infection is a major global health problem and eight genotypes (A to H) and multiples subtypes of HBV have been identified, and they show some distinct geographic distributions. The available data on HBV genotype in Iran are very heterogeneous and limited. Therefore in this...

  • Preface. Kukhanova, Marina // Current Pharmaceutical Design;Mar2000, Vol. 6 Issue 5, p1l 

    Introduces articles about scientific approaches on the rational design and development of antiviral drugs published in the March 2000 issue of the periodical 'Current Pharmaceutical Drug Design.' Design and evaluation of Hepatitis B virus inhibitors; Analysis of the catalytic cycle of HIV-1...

  • Rationale for Designing of Antigen-Specific Immune Therapy Including Dendritic Cell-Based Therapy in Patients with Chronic Hepatitis B Virus Infection. Akbar, Fazle; Murakami, Hidehiro; Horiike, Norio; Onji, Morikazu // Anti-Infective Agents in Medicinal Chemistry;2006, Vol. 5 Issue 1, p75 

    Approximately 350-400 million people of the world are chronically infected with the hepatitis B virus, and it is these individuals that harbor the virus for their whole life and are responsible for its transmission to uninfected populations. Considerable numbers of chronic hepatitis B virus...

  • Telbivudine. Dienstag, Jules; Easley, Chris; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Apr2007, Vol. 6 Issue 4, p267 

    Telbivudine (Tyzeka; Idenix/Novartis), a nucleoside analogue that inhibits the hepatitis B virus polymerase, was approved by the US FDA in October 2006 for the treatment of adults with chronic hepatitis B.

  • Traditional Chinese medicine and related active compounds: A review of their role on hepatitis B virus infection. Fanghua Qi; Zhixue Wang; Pingping Cai; Lin Zhao; Jianjun Gao; Norihiro Kokudo; Anyuan Li; Junqing Han; Wei Tang // Drug Discoveries & Therapeutics;Dec2013, Vol. 7 Issue 6, p212 

    Since the significant public health hazard of Hepatitis B virus (HBV) infection and obvious drug resistance and dose-dependent side effects for common antiviral agents (e.g., interferonalpha, lamivudine, and adefovir), continuous development of agents to treat HBV infection is urgently needed....


Read the Article


Sign out of this library

Other Topics